Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard versus model-guided antiviral therapy for chronic hepatitis C
2006-002483-26Phase 3Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Mar 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ribavirin in hepatitis C virus infection (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Number of weeks of therapy required for one sustained virological response. Started Mar 2007; status: terminated.
02
Drugs
ribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-002483-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002483-26.